Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II High Pulse Dose Clinical Trial of Orally Administered ITF2357 In Patients With Relapsed/Refractory Multiple Myeloma

NCT00792506 is registered in ClinicalTrials.gov with Italfarmaco as lead sponsor.

NCT NCT00792506
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00792506 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II High Pulse Dose Clinical Trial of Orally Administered ITF2357 In Patients With Relapsed/Refractory Multiple Myeloma
Lead sponsor
Italfarmaco
Phase
Phase 2
Overall status
Terminated
Start date
October 31, 2008
Completion date
July 31, 2010
Enrollment
1 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma